Savara (NASDAQ:SVRA) Posts Earnings Results, Misses Estimates By $0.02 EPS

Savara (NASDAQ:SVRA) posted its quarterly earnings results on Thursday. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02), Zacks reports. The company had revenue of $0.27 million during the quarter.

Savara Price Performance

NASDAQ:SVRA traded up $0.04 during trading hours on Friday, reaching $2.82. 119,305 shares of the company were exchanged, compared to its average volume of 1,284,856. The business has a 50 day moving average of $2.72 and a 200 day moving average of $3.27. Savara has a 1-year low of $2.26 and a 1-year high of $5.34. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The company has a market capitalization of $483.11 million, a P/E ratio of -6.56 and a beta of 0.60.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Wells Fargo & Company began coverage on shares of Savara in a research report on Friday, December 20th. They issued an “overweight” rating and a $8.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Savara in a report on Friday. Finally, JMP Securities restated a “market outperform” rating and issued a $9.00 price target on shares of Savara in a research note on Thursday, December 19th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $8.83.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.